DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 1 there's - 1 Victor Wenze Zhong - 1 Krista Varady - 1 Varady - 1 David Spiegelhalter - 1 Christopher D - 1 Gardner - 1
Top related locs:
Shanghai China Chicago Stanford United States Scotland
Top related orgs:
Shanghai Jiao Tong University School of Medicine - 2 American Heart Association - 2 Service - 1 University of Illinois Chicago - 1 University of Cambridge - 1 CNN - 1 Pennsylvania State University - 1 US Centers for Disease Control - 1

Search resuls for: "Shanghai Jiao Tong University School of Medicine"


4 mentions found


☆ A controversial study says intermittent fasting may shorten your lifespan. It shows how little we really know about the long-term effects.
  + stars: | 2024-03-18 | by ( ) www.businessinsider.com   time to read: +7 min
A new study links intermittent fasting to a higher risk of early death instead of longevity. While there's not yet enough evidence to say intermittent fasting is risky, the findings suggest we may have a lot more to learn about whether it's good for our health in the long run. However, some rigorous studies on intermittent fasting have found mixed results: some suggest it's no better for you than other diets, and isn't worth the side effects like hunger. people who follow the 16:8 diet — would have a lower risk of dying during the study, and better heart health. Advertisement"Overall, this study suggests that time-restricted eating may have short-term benefits but long-term adverse effects," Gardner said in a press release.
Persons: —, there's, Victor Wenze Zhong, Krista Varady, Varady, David Spiegelhalter, Christopher D, Gardner, Zhong Organizations: Service, Shanghai Jiao Tong University School of Medicine, American Heart Association, University of Illinois Chicago, University of Cambridge Locations: Shanghai, China, Chicago, Stanford
☆ Diet and sugary drinks boost risk of atrial fibrillation by up to 20%, study says
  + stars: | 2024-03-05 | by ( Sandee Lamotte | ) edition.cnn.com   time to read: +6 min
Atrial fibrillation is dangerous and on the riseAtrial fibrillation is the leading cause of stroke in the United States. Atrial fibrillation can also lead to blood clots, heart failure and “can increase the risk for heart attack, for dementia, for kidney disease. Replacing both diet and added sugar sodas with water is best to reduce chances of atrial fibrillation, experts say. The rate of atrial fibrillation in the US population is growing: The CDC estimates some 12 million Americans will have A-fib by 2030. “Do not take it for granted that drinking low-sugar and low-calorie artificially sweetened beverages is healthy, it may pose potential health risks.”
Persons: ”, Penny Kris, Etherton, Kris, “, Dr, Gregory Marcus, ” Marcus, Naveed Sattar, ” Sattar, Ningjian Wang, ” Wang Organizations: CNN, Pennsylvania State University, American Heart Association, US Centers for Disease Control, University of California, San Francisco School of Medicine, UCSF Health, Rhythm Society, University of Glasgow, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine Locations: United States, Scotland, Shanghai, China
☆ A promising new Covid pill shows key advantages over Paxlovid in trial
  + stars: | 2022-12-30 | by ( Aria Bendix | ) www.cnbc.com   time to read: +2 min
A new antiviral pill for Covid was found to be as effective as Paxlovid at curbing mild to moderate illness among people at high risk of severe disease in a Phase 3 trial in China. The results, published Wednesday in The New England Journal of Medicine, suggest that the treatment had fewer side effects than Paxlovid, the go-to antiviral for high-risk patients. Around 67% of people who took the experimental pill, called VV116, reported side effects, compared to to 77% who took Paxlovid. In the trial of VV116, more than 380 people took the experimental drug, while a similarly sized group took Paxlovid. The median time to recovery — defined as no Covid symptoms for two consecutive days — was four days for VV116 recipients and five days for those who took Paxlovid.
☆ A promising new Covid pill shows key advantages over Paxlovid in trials
  + stars: | 2022-12-29 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Aria-Bendix-Byline-Jm.Jpg | Aria Bendix | ) www.nbcnews.com   time to read: +5 min
Around 67% of people who took the experimental pill, called VV116, reported side effects, compared to to 77% who took Paxlovid. In the trial of VV116, more than 380 people took the experimental drug, while a similarly sized group took Paxlovid. The median time to recovery — defined as no Covid symptoms for two consecutive days — was four days for VV116 recipients and five days for those who took Paxlovid. Three-quarters of the trial participants were vaccinated, though the study found consistent results regardless of vaccine status. The National Institutes of Health recommends Paxlovid, with molnupiravir as an alternative in situations when neither Paxlovid nor remdesivir is available or appropriate.
0 next >>
Total: 4